Second malignancy in advanced or recurrent non-small cell lung cancer after the advent of molecular targeted drugs and immunotherapy. - Masui Y; Shukuya T; Kataoka S; Shiozaki H; Kurokawa K; Nakamura I; Miyawaki T; Koinuma Y; Asao T; Kanemaru R; Shimamura SS; Mimori T; et al. (Thoracic cancer, 2024)